Skip to main content
SpringerLink
Log in

Dolutegravir-related obesity increases adverse pregnancy outcomes

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Asif S, et al. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV. AIDS : 9 Jul 2021. Available from: URL: http://doi.org/10.1097/QAD.0000000000003020

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolutegravir-related obesity increases adverse pregnancy outcomes. Reactions Weekly 1866, 6 (2021). https://doi.org/10.1007/s40278-021-99702-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-99702-x

Search

Navigation